What pharmaceutical regulatory compliance covers
Pharmaceutical regulatory compliance is everything a drug company must do to keep its products lawfully on the market: make them correctly, report safety problems, promote them truthfully, track them through the supply chain and disclose financial relationships. Each area has its own rules, regulators and enforcement tools, and a gap in any one can halt a product or a company.
The main US obligations
| Area | Key requirements | Regulator | Recent development |
|---|---|---|---|
| Manufacturing quality | 21 CFR 210 and 211 (CGMP) | FDA | Unannounced foreign inspections expanded May 2025 (Hogan Lovells) |
| Safety reporting | 21 CFR 314.80 15-day and periodic reports | FDA | Unified Adverse Event Monitoring System launched March 2026 (FDA) |
| Advertising and promotion | FD&C Act, 21 CFR 202.1 | FDA (OPDP) | September 2025 crackdown on direct-to-consumer ads (King & Spalding) |
| Supply chain security | Drug Supply Chain Security Act | FDA | Small dispenser exemption extended to November 27, 2027 (Buchanan Ingersoll & Rooney) |
| Transparency | Open Payments (Sunshine Act) | CMS | $14.67 billion in payments across 17.07 million records published in 2026 (CMS) |
| Clinical trials | 21 CFR 50, 56, 312; ICH E6(R3) | FDA | FDA posted E6(R3) September 9, 2025 (UW Clinical Trials) |
| Trade and pricing | Section 232 tariffs, pricing agreements | Commerce, HHS | Tariffs on patented drugs from July 31, 2026, with exemptions tied to onshoring and pricing agreements (Crowell) |
Enforcement trends
Enforcement intensity rose sharply in 2025. Reed Smith counted 327 FDA warning letters from July 1 to December 3, 2025, “a 73% increase over the same period in 2024,” and reported that “The drug industry recorded 82 more warning letters compared to the prior year” (Reed Smith).
Promotion is a new front. On September 9, 2025, FDA and HHS announced “sweeping reforms to rein in misleading direct-to-consumer pharmaceutical advertisements,” sent a templated letter to thousands of companies and about 100 cease-and-desist letters, and said FDA would begin rulemaking on the “adequate provision loophole” for broadcast ads (King & Spalding).
Manufacturing remains the largest source of citations: the top FY2025 drug observation was quality unit procedures, with 243 citations (GMP Insiders).
Building a compliance program that holds up
- Map obligations by product, site and market, with an owner for each.
- Write procedures that reflect actual practice and current rules.
- Train by role, with records.
- Monitor and audit: GMP self-inspections, promotional review, safety reporting timeliness, Open Payments data quality.
- Investigate and correct through deviation, complaint and CAPA processes.
- Track regulatory change and update procedures promptly; 2025 and 2026 brought changes in advertising, GCP, DSCSA and trade.
- Report to leadership with metrics and resources for gaps.
What pharma compliance software should do
| Capability | Why it matters |
|---|---|
| Obligation and regulatory change tracking | Rules changed in several areas at once in 2025 and 2026 |
| Document control and training | Procedures and training records are the first things inspectors check |
| Deviation, complaint and CAPA workflows | Investigations are the second most cited GMP issue |
| Promotional review workflow | DTC enforcement is rising |
| Safety case management and reporting clocks | 15-day reporting deadlines |
| Transparency data management | Open Payments accuracy and dispute handling |
| Audit trails, Part 11 controls and validation | Required for GxP records |
| Evidence-based document review | Catches gaps between procedures and requirements |
Pharmaceutical compliance checklist
- Obligation register by product, site and market, with owners
- GMP, safety, promotion, supply chain and transparency procedures current
- Promotional materials reviewed against 2025 FDA expectations
- Safety reporting timeliness monitored
- DSCSA readiness confirmed with trading partners
- Open Payments data reviewed before submission
- Regulatory change monitoring assigned
- Compliance metrics reported to leadership
- Compliance software validated where it handles GxP records
Check compliance documents against current rules
When rules change in several areas at once, procedures fall behind. AskDona reviews SOPs, promotional review procedures, safety reporting procedures and quality agreements against FDA regulations, guidance or your own standards, flags outdated or missing requirements, and cites the passage behind every finding.
Run a sample compliance document assessment on one procedure set. AskDona shows the evidence; your compliance team decides.
FAQ
What is pharmaceutical regulatory compliance? Meeting all legal requirements that apply to making, testing, promoting, distributing and monitoring drugs.
Who enforces pharmaceutical compliance in the US? Mainly FDA, plus CMS for Open Payments, and other agencies for trade, pricing and fraud and abuse laws.
What changed in drug advertising compliance in 2025? FDA and HHS announced a crackdown on misleading DTC ads in September 2025 (King & Spalding).
What is pharma compliance software? Software that manages compliance obligations, documents, training, investigations, promotional review and reporting, with audit trails.
How much was reported under Open Payments? $14.67 billion across 17.07 million records published in 2026 (CMS).
References
All pages opened and checked by October 14, 2026.
| Source | Type | Date | Used for |
|---|---|---|---|
| Hogan Lovells: Unannounced foreign inspections | Law firm | May 8, 2025 | Inspection policy |
| FDA: AEMS launch | Regulator | Mar 11, 2026 | Safety reporting systems |
| King & Spalding: Advertising crackdown | Law firm | Sep 10, 2025 | DTC enforcement |
| Buchanan Ingersoll & Rooney: DSCSA extension | Law firm | Aug 14, 2026 | DSCSA |
| CMS: Open Payments data | Regulator | 2026 | Transparency totals |
| UW Clinical Trials: FDA publishes E6(R3) | Academic | Sep 16, 2025 | GCP |
| Crowell: Section 232 pharmaceutical tariffs | Law firm | Apr 7, 2026 | Trade |
| Reed Smith: FDA inspections in 2025 | Law firm | Dec 4, 2025 | Warning letter trend |
| GMP Insiders: FY2025 observations | Trade analysis | Jan 5, 2026 | GMP citations |